{
    "clinical_study": {
        "@rank": "50287", 
        "acronym": "MONALEESA-1", 
        "arm_group": [
            {
                "arm_group_label": "LEE011 400 mg + letrozole", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "LEE011 600 mg + letrozole", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Letrozole", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center, open-label Phase II randomized pre-surgical pharmacodynamics study."
        }, 
        "brief_title": "A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Early Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This randomized pre-surgical pharmacodynamics study will assess the biological activity of\n      LEE011 plus letrozole versus single agent letrozole in primary breast cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female patient is \u2265 18 years old at the time of informed consent, with newly\n             diagnosed resectable breast cancer, who received no prior therapy for breast cancer\n\n          -  Patient is postmenopausal. Postmenopausal status is defined either by:\n\n               -  Prior bilateral oophorectomy\n\n               -  Age \u226560\n\n               -  Age <60 and amenorrhea for 12 or more months and FSH (Follicle Stimulating\n                  Hormone) and estradiol in the postmenopausal range.\n\n          -  Patient has a histologically (and/or cytologically) confirmed diagnosis of\n             estrogen-receptor positive and/or progesterone receptor positive breast cancer by\n             local laboratory.\n\n          -  Patient has a grade II or grade III invasive breast cancer\n\n          -  Patient has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer\n             defined as a negative in situ hybridization test or an Immunohistochemistry (IHC)\n             status of 0, 1+ or 2+ (if IHC 2+, a negative in situ hybridization (respectively\n             FISH/CISH/SISH) test is required) by local laboratory testing\n\n          -  Patient has at least one breast lesion with a diameter of \u22651.0 cm by the most\n             accurate imaging modality used.\n\n          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\n        Exclusion Criteria:\n\n          -  Patient has received any prior therapy for breast cancer.\n\n          -  Patient has a concurrent malignancy or malignancy within 3 years of randomization,\n             with the exception of adequately treated, basal cell skin cancer or squamous cell\n             carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.\n\n          -  Patient has active cardiac disease or a history of cardiac dysfunction including any\n             of the following:\n\n               -  History of angina pectoris, symptomatic pericarditis, or myocardial infarction\n                  within 12 months prior to study entry\n\n               -  History of documented congestive heart failure (New York Heart Association\n                  functional classification III-IV)\n\n               -  Documented cardiomyopathy\n\n               -  Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by\n                  Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)\n\n               -  History of ventricular, supraventricular, nodal arrhythmias, or any other\n                  cardiac arrhythmias, Long QT Syndrome or conduction abnormality in the previous\n                  12 months.\n\n               -  Family history of QTc prolongation or of unexplainable sudden death at <50 years\n                  of age.\n\n               -  On screening 12 lead ECG, any of the following cardiac parameters: bradycardia\n                  (heart rate < 50 at rest), tachycardia (heart rate > 90 at rest), PR interval >\n                  220 msec, QRS interval >109 msec, or QTcF >450 msec.\n\n               -  Systolic blood pressure >160 mmHg or <90 mmHg.\n\n          -  Patient is currently receiving any of the following medications (see\n\n        Appendix 1 for details):\n\n          -  That are known strong inducers or inhibitors of CYP3A4.\n\n          -  That have a narrow therapeutic window and are predominantly metabolized through\n             CYP3A4.\n\n          -  That have a known risk to prolong the QT interval or induce Torsades de Pointes."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919229", 
            "org_study_id": "CLEE011A2201", 
            "secondary_id": "2013-002588-24"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LEE011 400 mg + letrozole", 
                    "LEE011 600 mg + letrozole"
                ], 
                "intervention_name": "LEE011", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LEE011 400 mg + letrozole", 
                    "LEE011 600 mg + letrozole", 
                    "Letrozole"
                ], 
                "intervention_name": "Letrozole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Letrozole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HR-positive", 
            "HER2-negative", 
            "Breast cancer", 
            "LEE011", 
            "Letrozole", 
            "CDK", 
            "CDK4", 
            "CDK6", 
            "CDK4/6", 
            "Pharmacodynamics", 
            "Pre-surgical", 
            "Postmenopausal"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "email": "rquinn@uabmc.edu", 
                    "last_name": "Rebecca Quinn", 
                    "phone": "205-934-3866"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama at Birmingham SC"
                }, 
                "investigator": {
                    "last_name": "Andres Forero-Torres", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hkinser@hogonc.com", 
                    "last_name": "Holly M. Kinser", 
                    "phone": "+1 479 872 8130"
                }, 
                "facility": {
                    "address": {
                        "city": "Fayetteville", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72703"
                    }, 
                    "name": "Highlands Oncology Group SC"
                }, 
                "investigator": {
                    "last_name": "Joseph Thaddeus Beck", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kmkelly@mednet.ucla.edu", 
                    "last_name": "Kimberly M. Kelly", 
                    "phone": "+1 310 582 6324"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California at Los Angeles UCLA SC"
                }, 
                "investigator": {
                    "last_name": "Sara Alsterlind Hurvitz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "collierj@uic.edu", 
                    "last_name": "Jennifer Collier", 
                    "phone": "312-355-5112"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "University of Illinois Cancer Center at Chicago SC"
                }, 
                "investigator": {
                    "last_name": "Kent Hoskins", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rhepp@partners.org", 
                    "last_name": "Rachel Hepp", 
                    "phone": "617-724-0878"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital SC-9"
                }, 
                "investigator": {
                    "last_name": "Aditya Bardia", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "alange@acornresearch.net", 
                    "last_name": "Amy Lange", 
                    "phone": "901-683-0055"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38120"
                    }, 
                    "name": "The West Clinic SC-4"
                }, 
                "investigator": {
                    "last_name": "Lee S. Schwartzberg", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kristie@nashvillebreastcenter.com", 
                    "last_name": "Kristie Appleton"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Advantage Clinical Research SC"
                }, 
                "investigator": {
                    "last_name": "Pat Whitworth Jr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "amherrick@mdanderson.org", 
                    "last_name": "Ashley Herrick", 
                    "phone": "713-794-1014"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas/MD Anderson Cancer Center Dept of MD Anderson (8)"
                }, 
                "investigator": {
                    "last_name": "Funda Meric-Bernstam", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilrijk", 
                        "country": "Belgium", 
                        "zip": "2610"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier Cedex 5", 
                        "country": "France", 
                        "zip": "34298"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Herblain cedex", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20141"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20132"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "PD", 
                        "zip": "35100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3075 EA"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584CX"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "169610"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08003"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "France", 
                "Italy", 
                "Netherlands", 
                "Singapore", 
                "Spain"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products (FAMPHP)", 
                "Spain: The Spanish Agency of Medicines and Medical Devices (AEMPS)", 
                "Italy: Italian Medicines Agency."
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cell cycle response rate is defined by proportion of patients with natural logarithm of Ki-67 levels (expressed as percentage of baseline values) of less than 1 at the time of surgery", 
            "measure": "Cell cycle response rate", 
            "safety_issue": "No", 
            "time_frame": "Day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919229"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Occurrence, frequency and severity of adverse events (AEs), laboratory abnormalities", 
                "measure": "Safety and tolerability of the combination", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after the last dose"
            }, 
            {
                "measure": "Change from baseline in electrocardiogram (ECG) parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Day 14"
            }, 
            {
                "measure": "Change from baseline in expression of Retinoblastoma Protein (pRB)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 15"
            }, 
            {
                "measure": "PK (pharmacokinetics) parameters, including but not limited to, Cmax, Tmax, AUClast for LEE011 (and any relevant metabolites) and letrozole.", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 8, 14 and 15"
            }, 
            {
                "measure": "Change in ECG morphology", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Day 14"
            }, 
            {
                "description": "Correlation between the QTc interval change from baseline and plasma concentrations of LEE011 and/or any relevant metabolites", 
                "measure": "Correlation between PK concentrations and ECG changes", 
                "safety_issue": "Yes", 
                "time_frame": "Day 14"
            }, 
            {
                "measure": "Change from baseline in expression of Cyclin-Dependent Kinase 1 (CDK1)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 15"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}